Physician profile
Basir Ul Haque
NPI 1912131723
$959.35
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $130 · 2021: $11.92 · 2023: $38.67 · 2024: $24.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $38.67 · Food and Beverage: $24.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $38.67 |
| Food and Beverage | $24.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $108.44 | 2019-2020 | |
| Foundation Medicine, INC. | $92.66 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $88.22 | 2019 | |
| Janssen Biotech, INC. | $84.09 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $81.38 | 2019-2023 | Opdivo |
| Pfizer INC. | $58.35 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $57.35 | 2019 | |
| Merck Sharp & Dohme LLC | $48.36 | 2019 | |
| Amgen INC. | $40.50 | 2019-2020 | |
| Seagen INC. | $26.31 | 2020 | |
| Abbott Laboratories | $24.64 | 2024 | Freestyle Libre 3 |
| Taiho Oncology, INC. | $24.59 | 2019 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Abbvie INC. | $20.51 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.98 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $19.56 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.75 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.47 | 2019 | |
| Rigel Pharmaceuticals, INC. | $17.29 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2019 | |
| Emd Serono, INC. | $16.83 | 2019 | |
| Kite Pharma, INC. | $15.87 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $14.84 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $12.42 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basir Haque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.